酒精使用障碍中高抗奖赏情感的去甲肾上腺素能机制与神经环路
本综述探讨去甲肾上腺素能功能障碍在酒精使用障碍(AUD)各阶段高抗奖赏情感(hyperkatifeia)中的作用,指出去甲肾上腺素能系统存在关键性别二态性,证据支持优先开发去甲肾上腺素特异性药物,并识别可能获益最大的AUD亚群(如女性或合并慢性疼痛或焦虑/应激障碍者)。
要点
- 高抗奖赏情感是驱动成瘾的重要概念框架,戒断期出现并可迁延至长期戒断促复发。
- 去甲肾上腺素能功能障碍与AUD、焦虑、慢性应激、抑郁及情绪和躯体疼痛相关。
- 去甲肾上腺素能系统存在关键性别二态性,可能差异影响女性和男性AUD的发展与轨迹。
核心结论
- 证据支持优先开发去甲肾上腺素特异性药物以治疗AUD,并识别可能从中获益最大的AUD亚群(如女性或合并慢性疼痛或焦虑/应激障碍者)。
研究设计与样本
- 本综述讨论既往和近期关于去甲肾上腺素能影响AUD周期各阶段(暴饮/中毒、戒断/负性情绪、 preoccupation/期待)的研究,以高抗奖赏情感为视角。
主要发现
- 去甲肾上腺素能功能障碍涉及AUD、焦虑、慢性应激、抑郁以及情绪和躯体疼痛。
- 去甲肾上腺素能系统内存在关键性别二态性,被认为差异影响女性和男性AUD的发展与轨迹。
- 既往和近期研究探讨了去甲肾上腺素能在AUD周期各阶段(暴饮/中毒、戒断/负性情绪、preoccupation/期待)中的影响。
临床怎么用
- 作者认为证据支持优先开发去甲肾上腺素特异性药物以治疗AUD,并识别可能获益最大的AUD亚群(如女性或合并慢性疼痛或焦虑/应激障碍者)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperkatifeia, the manifestation of emotional distress or pain, is a conceptual framework gaining traction throughout the alcohol and other substance use fields as an important driver of addiction. It is well known that previous or current negative life experiences can serve as powerful motivators for excessive alcohol consumption and precipitate the development of an alcohol use disorder (AUD). A major hallmark of later stages of AUD is the emergence of hyperkatifeia during withdrawal, which can persist well into protracted abstinence to drive relapse. Given these complex interactions, understanding the specific neuroadaptations that lie at the intersection of hyperkatifeia and AUD can inform ongoing therapeutic development. The monoamine norepinephrine is of particular interest. Noradrenergic dysfunction is implicated in AUD, anxiety, chronic stress, depression, and emotional and physical pain. Importantly, there are key sexual dimorphisms within the noradrenergic system that are thought to differentially impact the development and trajectory of AUD in women and men. In the current review, we discuss past and recent work on noradrenergic influences at each stage of the AUD cycle (binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation) through the lens of hyperkatifeia. Evidence from these studies support the prioritization of norepinephrine-specific drug development to treat AUD and the identification of AUD subpopulations that may benefit the most from these therapies (e.g., women or people with comorbid chronic pain or anxiety/stress disorders).
引用
- Varodayan FP, Erikson CM, Scroger MV, et al. Noradrenergic Mechanisms and Circuitry of Hyperkatifeia in Alcohol Use Disorder. Biol Psychiatry. 2024. PMID: 39304172. doi:10.1016/j.biopsych.2024.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。